Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Yкраї́нська
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
  • Communities & Collections
  • All of DSpace
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Yкраї́нська
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Masika Anna Mahinda"

Now showing 1 - 1 of 1
Results Per Page
Sort Options
  • Loading...
    Thumbnail Image
    Item
    Long-Acting Antiretroviral Therapies for HIV Treatment and Prevention: Efficacy and Implementation
    (Newport International Journal of Biological and Applied Sciences (NIJBAS), 2026) Masika Anna Mahinda
    Human immunodeficiency virus (HIV) infection remained a persistent global health challenge despite significant progress in antiretroviral therapy. While daily oral antiretroviral regimens have substantially improved survival and reduced transmission, long-term adherence difficulties continue to compromise treatment and prevention outcomes. Long-acting antiretroviral therapies emerged as an innovative pharmacological approach aimed at overcoming these limitations. This review examined the biochemical rationale, clinical efficacy, and implementation considerations of long-acting antiretroviral therapies for both HIV treatment and prevention. A narrative review methodology was utilized to synthesize and critically analyze existing scientific literature on long-acting antiretroviral agents, including pharmacological studies, clinical trials, and implementation research. Evidence indicated that long-acting antiretroviral therapies achieved virologic suppression comparable to conventional oral regimens while offering advantages in adherence, patient satisfaction, and prevention efficacy. Injectable long-acting agents also demonstrated superior effectiveness in HIV prevention compared to daily oral pre-exposure prophylaxis. Nonetheless, challenges related to resistance risk, healthcare infrastructure, cost, and equitable access persist. Longacting antiretroviral therapies represented a transformative advancement in HIV care, but their optimal impact will depend on strategic implementation and health system adaptation.

KIU INSTITUTIONAL REPOSITORY copyright © 2002-2026

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback